ClinicalTrials.gg

Program

LXE408

In Novartis's pipeline, Proteasome inhibitor. Its studies are mostly in Chagas Disease · Leishmaniasis, Visceral, led by Novartis.

Furthest: phase 2, since Oct 7, 20242 company-led studies, 1 open or runningNext primary completion: Jul 22, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis21 open or runningphase 2since Oct 7, 2024Oct 7, 2024Jul 22, 2027phase 2 · NCT06632600
  • Named in Novartis’s own pipeline as LXE408, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 7, 2024First study: phase 2 study in Chagas DiseaseFirst studyNCT06632600 · 130 planned · United States, Argentina, Brazil and more
  2. Aug 26, 2026Phase 1 study in Leishmaniasis, VisceralNCT07809919 · 88 enrolled · United States

Ahead

  1. Jul 22, 2027Primary completion: phase 2 study in Chagas DiseaseNCT06632600

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07809919Leishmaniasis, Visceral · United States1CompletedSep 27, 202188
NCT06632600Chagas Disease · United States, Argentina, Brazil and more2RecruitingJul 22, 2027130

How it is read

Names in the registry

  • “LXE408”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.